Blood Test Study to Detect Early Blood Cancers
Tests a blood sample screen for blood cancers in adults, including people at risk.
Plain-language title generated from the registry record
Registry title: Early Detection and Screening of Hematological Malignancies - SANGUINE
Key facts
- Where
- Athens, GreeceSee the site
Where in Greece
- National and Kapodistrian University of Athens (NKUA)Athens, GreeceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- JaxBio Ltd
- Trial code
- NCT05735704
- Record updated
- 15 October 2026
- Original description
This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions [smoldering MM (SMM) and monoclonal gammopathy of undetermined significance (MGUS)], Hodgkin lymphoma (HL), diffuse large B cell lymphoma (DLBCL), Follicular lymphoma (FL), Marginal Zone lymphomas (MZL), acute myeloid leukemia (AML)*, myelodysplastic syndrome (MDS), subjects at risk and control subjects with no malignant disease.Read full original descriptionShow less
Early Detection and Screening of Hematological Malignancies - SANGUINE
This is a multicenter, open-label, non-interventional controlled study to identify and characterize the epigenetic signatures for a set of hematological malignancies: Multiple myeloma (MM), pre-MM conditions [smoldering MM (SMM) and monoclonal gammopathy of undetermined significance (MGUS)], Hodgkin lymphoma (HL), diffuse large B cell lymphoma (DLBCL), Follicular lymphoma (FL), Marginal Zone lymphomas (MZL), acute myeloid leukemia (AML)*, myelodysplastic syndrome (MDS), subjects at risk and control subjects with no malignant disease.
*Patients with a diagnosis of acute promyelocytic leukemia (APL) are not included
Inclusion: General criteria for all study populations:; Male and female subjects ≥18 years of age; Ability to understand and willingness to sign a written informed consent document; For Patients with hematological malignancies:; Patients who have been diagnosed, have measurable disease, and/or are being monitored/followed up due to one of the following conditions: MM, pre-MM conditions (SMM and MGUS), HL, DLBCL, FL, MZL, AML, MDS that did not yet undergo any treatment; NOTE:; Patients diagnosed with DLBCL that is transformed from FL or MZL, and patients diagnosed with AML secondary to MDS or MPN, who were treated for their primary disease (FL/MZL/MDS/MPN) before study enrollment, are eligible; For subjects at risk for developing the investigated hematological malignancies:; First-degree relatives; AND /OR; Elderly subjects ≥ 65 years of age.
Exclusion: Patients/subjects with active inflammatory autoimmune disease that requires treatment with immunosuppressive/ immunomodulation agents; Patients/subjects with current co-diagnosis of another type of cancer; Patients/subjects with a known active or prior cancer (other than defined as study population), occurring within the last 2 years (even if considered to be in complete remission). Patients/subjects with non- melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection; Patients/subjects with known human immunodeficiency virus (HIV) positive; Patients/subjects with known active Hepatitis A/B/C or past hepatitis C; Patients with a diagnosis of acute promyelocytic leukemia (APL); Subjects that are likely to be noncompliant with the protocol, or felt to be unsuitable by the investigator for any other reason.